Viridian Therapeutics, Inc. (VRDN)
Automate Your Wheel Strategy on VRDN
With Tiblio's Option Bot, you can configure your own wheel strategy including VRDN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRDN
- Rev/Share 0.0037
- Book/Share 7.4311
- PB 1.9755
- Debt/Equity 0.0351
- CurrentRatio 19.487
- ROIC -0.5368
- MktCap 1197770560.0
- FreeCF/Share -3.4464
- PFCF -4.2725
- PE -3.873
- Debt/Assets 0.0321
- DivYield 0
- ROE -0.4908
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VRDN | Wells Fargo | Overweight | Equal Weight | $37 | $27 | Dec. 19, 2024 |
| Reiterated | VRDN | Needham | -- | Buy | $30 | $38 | Sept. 11, 2024 |
News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 23,400 shares of the company's common stock to one new employee (th.
Read More
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.79 per share a year ago.
Read More
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2025. “We continue to execute across the portfolio as we work towards submitting the veligrotug BLA in the second half of 2025, advancing our VRDN-003 subcutaneous clinical tri.
Read More
About Viridian Therapeutics, Inc. (VRDN)
- IPO Date 2014-06-18
- Website https://www.viridiantherapeutics.com
- Industry Biotechnology
- CEO Mr. Stephen F. Mahoney J.D., MBA
- Employees 143